SC
PNT

Shay Capital’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Shay Capital’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,000
Closed -$120K – 657
2022
Q1 		$120K Buy
+15,000
New +$95.2K 0.02% 417

Other funds holding PNT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Shay Capital's PNT Position: Q2 2022 in Review

Shay Capital sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q2 2022, closing a stake of 15,000 shares — an estimated $120K sold.

Shay Capital first reported a position in PNT in Q1 2022 and held it in 1 quarter. The position peaked at $120K in Q1 2022. 84 funds tracked by Wall St. Rank hold PNT as of Q2 2022.

  • Shay Capital reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Shay Capital sold 15,000 POINT Biopharma Global Inc. Common Stock shares in Q2 2022, an estimated $120K.
  • Shay Capital first reported a position in POINT Biopharma Global Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Shay Capital's POINT Biopharma Global Inc. Common Stock position peaked at $120K in Q1 2022.
  • 84 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q2 2022.

Based on Shay Capital's 13F filing for Q2 2022, filed 15 Aug 2022.